Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Impact of O6-methylguanine-DNA Methyltransferase (MGMT) Promoter Methylation and MGMT Expression on Dacarbazine Treated Sarcoma Patients (MGMT)

NCT04893356 is registered in ClinicalTrials.gov with National Cancer Institute, Naples as lead sponsor.

NCT NCT04893356
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04893356 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Impact of O6-methylguanine-DNA Methyltransferase (MGMT) Promoter Methylation and MGMT Expression on Dacarbazine Treated Sarcoma Patients (MGMT)
Lead sponsor
National Cancer Institute, Naples
Phase
Observational
Overall status
Unknown status
Start date
January 20, 2021
Completion date
January 20, 2025
Enrollment
75 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

sarcoma